Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05742295
Other study ID # Vit. K for SULBinCo
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date February 25, 2023
Est. completion date October 5, 2023

Study information

Verified date October 2023
Source Helwan University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Evaluating the effect of prophylactic doses of vitamin K in preventing the adverse effect of cefoperazone/sulbactam induced coagulopathy in critically ill patients.


Description:

One of the most challenging issues in the intensive care unit is treating multidrug-resistant (MDR) bacterial infections weighing benefit to risk ratio. MDR bacterial infection in ICU is a major public health problem and the main cause of mortality in ICUs in Egypt. A study published in the American Journal of Infection Control pointed out that the prevalence of MDR bacterial infections in the ICU was 54%. Cefoperazone is a 3rd generation cephalosporin antibiotic covering many Gram-positive and Gram-negative bacteria, sulbactam is a beta-lactamase inhibitor which is used in combination with many antibiotics to overcome beta-lactamase producing bacteria, therefore the combination of cefoperazone/sulbactam has activity against MDR gram-negative bacteria. On the other hand, cefoperazone has been shown to have the adverse effects of inducing coagulopathy which is reported in many case reports and retrospective cohort studies. In most cases, coagulopathy events occur within a few days from the start of using cefoperazone/sulbactam, therefore the ICU staff was obliged to discontinue the antibiotic and choose another alternative leading to increasing the risk of resistant bacteria and treatment failure. Therefore, discontinuing the antibiotic due to its serious adverse events will lead to poor outcomes, more bacterial resistance, and more cost therapeutic plans for treating the infection and managing the severe adverse drug events which have been occurred such as bleeding. There are 2 mechanisms for cefoperazone-induced coagulopathy. The first the mechanism is related to N-methylthiotetrazole (NMTT), a side chain in cefoperazone molecule, which is responsible for the inhibition of a vitamin K-dependent carboxylation process leading to antagonizing blood clotting factors. The the second mechanism is antibiotics, in general, kill the normal flora in the gut which produce vitamin K. This cefoperazone/sulbactam-induced coagulopathy is not found in healthy volunteers or patients with adequate vitamin K activity, therefore, could consider cefoperazone/sulbactam-induced coagulopathy in critically ill patients, as related to nutritional status of these patients specifically with regard to vitamin K. This study aimed at studying the effect of co-administration of prophylactic doses of vitamin k during the administration of cefoperazone/sulbactam to keep the normal daily requirements of vitamin k, therefore preventing coagulopathy.


Recruitment information / eligibility

Status Completed
Enrollment 56
Est. completion date October 5, 2023
Est. primary completion date October 5, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - ICU admitted patients on treatment or prophylactic doses of cefoperazone/sulbactam. Exclusion Criteria: - Patients' aged <18 years - Pregnancy or breastfeeding women - Active bleeding or bleeding disorder - Patients having an abnormal baseline coagulation profile. - Patients administer total parenteral nutrition with regular vitamin k supplements. - Refusal to sign the written informed consent.

Study Design


Intervention

Drug:
Vitamin K
Coadministration of vitamin K with the first dose of cefoperazone/sulbactam

Locations

Country Name City State
Egypt 6-October Hospital Giza

Sponsors (1)

Lead Sponsor Collaborator
Helwan University

Country where clinical trial is conducted

Egypt, 

References & Publications (11)

Abdelkader MM, Aboshanab KM, El-Ashry MA, Aboulwafa MM. Prevalence of MDR pathogens of bacterial meningitis in Egypt and new synergistic antibiotic combinations. PLoS One. 2017 Feb 16;12(2):e0171349. doi: 10.1371/journal.pone.0171349. eCollection 2017. — View Citation

Allison PM, Mummah-Schendel LL, Kindberg CG, Harms CS, Bang NU, Suttie JW. Effects of a vitamin K-deficient diet and antibiotics in normal human volunteers. J Lab Clin Med. 1987 Aug;110(2):180-8. — View Citation

Cai Z, Yang W, He Y, Chen Q, Wang S, Luo X, Wang X. Cefoperazone/Sulbactam-Induced Abdominal Wall Hematoma and Upper Gastrointestinal Bleeding: A Case Report and Review of the Literature. Drug Saf Case Rep. 2016 Dec;3(1):2. doi: 10.1007/s40800-016-0025-9. — View Citation

Fouda R, Soliman MS, ElAnany MG, Abadeer M, Soliman G. Prevalence and risk factors of MRSA, ESBL and MDR bacterial colonization upon admission to an Egyptian medical ICU. J Infect Dev Ctries. 2016 Apr 28;10(4):329-36. doi: 10.3855/jidc.6798. — View Citation

Hu HR. Fatal Vitamin K-Dependent Coagulopathy Associated with Cefoperazone/Sulbactam: A Case Report. Drug Saf Case Rep. 2019 Jun 14;6(1):6. doi: 10.1007/s40800-019-0100-0. — View Citation

Mendes R, Policarpo S, Fortuna P, Alves M, Virella D, Heyland DK; Portuguese NUTRIC Study Group. Nutritional risk assessment and cultural validation of the modified NUTRIC score in critically ill patients-A multicenter prospective cohort study. J Crit Care. 2017 Feb;37:45-49. doi: 10.1016/j.jcrc.2016.08.001. Epub 2016 Aug 10. — View Citation

Park GH, Kim S, Kim MS, Yu YM, Kim GH, Lee JS, Lee E. The Association Between Cephalosporin and Hypoprothrombinemia: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2019 Oct 16;16(20):3937. doi: 10.3390/ijerph16203937. — View Citation

Schentag JJ, Welage LS, Grasela TH, Adelman MH. Determinants of antibiotic-associated hypoprothrombinemia. Pharmacotherapy. 1987;7(3):80-6. doi: 10.1002/j.1875-9114.1987.tb03522.x. — View Citation

Schentag JJ, Welage LS, Williams JS, Wilton JH, Adelman MH, Rigan D, Grasela TH. Kinetics and action of N-methylthiotetrazole in volunteers and patients. Population-based clinical comparisons of antibiotics with and without this moiety. Am J Surg. 1988 May 31;155(5A):40-4. doi: 10.1016/s0002-9610(88)80210-1. — View Citation

Talaat M, El-Shokry M, El-Kholy J, Ismail G, Kotb S, Hafez S, Attia E, Lessa FC. National surveillance of health care-associated infections in Egypt: Developing a sustainable program in a resource-limited country. Am J Infect Control. 2016 Nov 1;44(11):1296-1301. doi: 10.1016/j.ajic.2016.04.212. Epub 2016 Jun 20. — View Citation

Wang W, Liu Y, Yu C, Tan J, Xiong W, Dong D, Li S, Zhang R, Li J, Wu Y, Zong Z, Su N, Zou K, Wu G, Sun X. Cefoperazone-sulbactam and risk of coagulation disorders or bleeding: a retrospective cohort study. Expert Opin Drug Saf. 2020 Mar;19(3):339-347. doi: 10.1080/14740338.2020.1713090. Epub 2020 Jan 27. — View Citation

* Note: There are 11 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants with changes in INR level comparing INR level between baseline INR (before starting the antibiotic) and during the treatment with the antibiotic During the duration of cefoperazone/sulbactam treatment up to 2 weeks
Secondary Number of Participants with bleeding incidence Internal bleeding as hematemesis or melena During the duration of cefoperazone/sulbactam treatment up to 2 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04081792 - Optimal Antibiotics for Operated Diabetic Foot Infections N/A
Recruiting NCT05499481 - Short Against Long Antibiotic Therapy for Infected Orthopedic Sites Phase 3
Recruiting NCT05950984 - Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
Completed NCT03199911 - Topical Antibiotic Prophylaxis for Eyelids Phase 4
Completed NCT05355571 - The Impact of Probiotic Supplementation on Antibiotic Induced Changes in Gastrointestinal Function and/or Faecal Microbiota Composition N/A
Recruiting NCT05699174 - PO vs IV Antibiotics for the Treatment of Infected Nonunion of Fractures After Fixation Phase 3
Completed NCT03087890 - Impact of Cotrimoxazole Use in Immunocompetent HIV Patients on Carriage of Antimicrobial Resistant Bacteria Phase 4
Completed NCT01254097 - Probiotics in Primary Care N/A
Recruiting NCT06018792 - Molecular Culture for the Diagnosis of Pediatric Sepsis
Completed NCT06030713 - Timing of Maternal Antibiotic Prophylaxis During a Cesarean Section and the Early Infant Gut Microbiome N/A
Active, not recruiting NCT05027893 - Complications After Lower Third Molar Surgery N/A
Not yet recruiting NCT03935828 - Effect of Topical Sinonasal Antibiotics Phase 2
Not yet recruiting NCT06383637 - Antibiotic Use and Resistance KAP Among Dental Interns
Enrolling by invitation NCT04707092 - Use of Preoperative and Postoperative Antimicrobial Treatment Phase 4
Not yet recruiting NCT06395454 - Usage of Procalcitonin to Reduce Antibiotics Duration in VAP in Neurosurgical ICU N/A
Recruiting NCT03932708 - Improving Antibiotic Use in Urgent Care Facilities N/A
Recruiting NCT04731025 - Local Antibiotics for Breast Implants Phase 3
Completed NCT04403334 - Postoperative Safety Outcomes of Intraoperative Intracameral Preservative-Free Moxifloxacin Versus Levofloxacin Phase 4
Completed NCT04127682 - Antibiotic Prescription for Children With Acute Upper Respiratory Tract Infections in Assiut District
Not yet recruiting NCT06250413 - Autoflor -Lyophilized Capsulated Autological FMT to Restore Gut Microbiome After Treatment With Antibiotics N/A